MedTrace Logo

Avanz Phleum Pratense Maintenance Dose

NCT01438827 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2014-01-22

No results posted yet for this study

Summary

The purpose of the trial is to evaluate the efficacy of two dosing schedules of Avanz SQ+ (Standardised Quality) Phleum pratense compared to placebo in subjects with grass pollen induced allergic rhinoconjunctivitis with or without asthma.

Conditions

  • Allergic Rhinoconjunctivitis

Interventions

DRUG

Avanz Phleum pratense

Suspension for Injection, Every 6 weeks for one year

DRUG

Placebo

Suspension for Injection, Every 6 weeks for one year

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Jörg Kleine-Tebbe, PD Dr. · Clinical Research Center for Dermatology, Allergy and Asthma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-12-31
Completion
2013-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01438827 on ClinicalTrials.gov